Related references
Note: Only part of the references are listed.Cardiovascular Disease in Adult Survivors of Childhood Cancer
Steven E. Lipshultz et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Subclinical Cardiotoxicity in Childhood Cancer Survivors Exposed to Very Low Dose Anthracycline Therapy
Kasey Leger et al.
PEDIATRIC BLOOD & CANCER (2015)
Childhood and adolescent cancer statistics, 2014
Elizabeth Ward et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Aging and Risk of Severe, Disabling, Life-Threatening, and Fatal Events in the Childhood Cancer Survivor Study
Gregory T. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron
Tomáš Šimůnek et al.
Pharmacological Reports (2014)
Anthracycline cardiotoxicity in survivors of childhood cancer: Clinical course, protection, and treatment
Neha Bansal et al.
PROGRESS IN PEDIATRIC CARDIOLOGY (2014)
Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence
Steven E. Lipshultz et al.
PROGRESS IN PEDIATRIC CARDIOLOGY (2014)
A review of the preclinical development of dexrazoxane
Eugene H. Herman et al.
PROGRESS IN PEDIATRIC CARDIOLOGY (2014)
Balancing the oncologic effectiveness versus the cardiotoxicity of anthracycline chemotherapy in childhood cancer
Steven D. Colan et al.
PROGRESS IN PEDIATRIC CARDIOLOGY (2014)
Oxidative Stress, Redox Signaling, and Metal Chelation in Anthracycline Cardiotoxicity and Pharmacological Cardioprotection
Martin Sterba et al.
ANTIOXIDANTS & REDOX SIGNALING (2013)
Impact of Hemochromatosis Gene Mutations on Cardiac Status in Doxorubicin-Treated Survivors of Childhood High-Risk Leukemia
Steven E. Lipshultz et al.
CANCER (2013)
Modifiable Risk Factors and Major Cardiac Events Among Adult Survivors of Childhood Cancer
Gregory T. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: A north American perspective
Etan Orgel et al.
PEDIATRIC BLOOD & CANCER (2013)
Cranial Irradiation as an Additional Risk Factor for Anthracycline Cardiotoxicity in Childhood Cancer Survivors: An Analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study
David C. Landy et al.
PEDIATRIC CARDIOLOGY (2013)
Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease
Saro H. Armenian et al.
BLOOD (2012)
Dexrazoxane for the Prevention of Cardiac Toxicity and Treatment of Extravasation Injury from the Anthracycline Antibiotics
James H. Doroshow
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2012)
Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients
Minkyoung Kang et al.
JOURNAL OF CHEMOTHERAPY (2012)
Cardiovascular Status of Childhood Cancer Survivors Exposed and Unexposed to Cardiotoxic Therapy
Steven E. Lipshultz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes
Steven E. Lipshultz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
High Risk of Symptomatic Cardiac Events in Childhood Cancer Survivors
Helena J. van der Pal et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes-A Report From the Children's Oncology Group
Javier G. Blanco et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Sui Zhang et al.
NATURE MEDICINE (2012)
Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: A report from the Children's Oncology Group
Cameron K. Tebbi et al.
PEDIATRIC BLOOD & CANCER (2012)
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes
Steven E. Lipshultz et al.
PEDIATRICS (2012)
Preventing and Treating Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer
Melissa B. Diamond et al.
CURRENT CANCER THERAPY REVIEWS (2012)
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium
Lynda M. Vrooman et al.
EUROPEAN JOURNAL OF CANCER (2011)
Role of Cancer Treatment in Long-Term Overall and Cardiovascular Mortality After Childhood Cancer
Markhaba Tukenova et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Dexrazoxane for Preventing Anthracycline Cardiotoxicity in Children with Solid Tumors
Hyoung Soo Choi et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2010)
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial
Steven E. Lipshultz et al.
LANCET ONCOLOGY (2010)
Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group
W. L. Salzer et al.
LEUKEMIA (2010)
Mechanisms of Anthracycline Cardiac Injury: Can We Identify Strategies for Cardioprotection?
Douglas B. Sawyer et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2010)
A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425
Cindy L. Schwartz et al.
BLOOD (2009)
Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort
Daniel A. Mulrooney et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane
Elly V. Barry et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cause-specific late mortality among 5-year survivors of childhood cancer: The childhood cancer survivor study
Ann C. Mertens et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Dexrazoxane-Associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease
Cameron K. Tebbi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Chronic health conditions in adult survivors of childhood cancer
Kevin C. Oeffinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Cardioprotective effect of dexrazoxane during treatment with doxorubicin:: A study using low-dose dobutamine stress echocardiography
MG Paiva et al.
PEDIATRIC BLOOD & CANCER (2005)
Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines
JH Silber et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Does anthracycline administration by infusion in children affect late cardiotoxicity?
GA Levitt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia
SE Lipshultz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers
M Gupta et al.
MEDICAL AND PEDIATRIC ONCOLOGY (2003)
Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer
SE Lipshultz et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Doxorubicin administration by continuous infusion is not cardioprotective: The Dana-Farber 91-01 acute lymphoblastic leukemia protocol
SE Lipshultz et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
